SF2809 Compounds, Novel Chymase Inhibitors from Dactylosporangium sp. 1. Taxonomy, Fermentation, Isolation and Biological Properties
-
- TANI MASATO
- Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd.
-
- GYOBU YASUHIRO
- Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd.
-
- SASAKI TORU
- Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd.
-
- TAKENOUCHI OSAMI
- Teijin Institute for Biomedical Research, Teijin Ltd.
-
- KAWAMURA TAKASHI
- Teijin Institute for Biomedical Research, Teijin Ltd.
-
- KAMIMURA TAKASHI
- Teijin Institute for Biomedical Research, Teijin Ltd.
-
- HARADA TOSHIAKI
- Teijin Institute for Biomedical Research, Teijin Ltd.
書誌事項
- タイトル別名
-
- 1. Taxonomy, Fermentation, Isolation and Biological Properties
この論文をさがす
説明
Six novel chymase inhibitors, SF2809-I, SF2809-II, SF2809-III, SF2809-IV, SF2809-V and SF2809-VI, were isolated from the fermentation broth of an actinomycete strain SF2809. The strain was identified as Dactylosporangium sp. by morphological, chemotaxonomical and phylogenetic studies. These six novel compounds inhibited recombinant human chymase in the range between IC50 of 0.014 and 7.3μM. However, they showed little or no inhibitory activity against chymotrypsin or cathepsin G, even though these two and chymase belong to the chymotryptic serine protease family. This result indicates that these compounds work as specific chymase inhibitors.
収録刊行物
-
- The Journal of Antibiotics
-
The Journal of Antibiotics 57 (2), 83-88, 2004
公益財団法人 日本感染症医薬品協会